Literature DB >> 18085426

Mineral and bone disorder after renal transplantation: a review.

Hazim Sadideen1, Adrian Covic, David Goldsmith.   

Abstract

Chronic kidney disease-mineral bone disorder is a common clinical picture encountered in patients with end-stage renal disease and is the result of additive pathophysiological processes. Renal transplantation remains the treatment of choice for these patients, especially as advances in this field have allowed for enhanced allograft survival. However, with increasing success of renal transplantation has come a greater appreciation of some of its subsequent complications, such as posttransplantation bone disease. Recently, persistent hyperparathyroidism and osteopenia-osteoporosis have been given specific attention. Traditionally, persistent hyperparathyroidism has been treated with parathyroidectomy, although the role that calcimimetics may play in the future is promising. Newer aspects to medical management of osteopenia-osteoporosis, such as the efficacy of bisphosphonate therapy and early steroid withdrawal, are becoming apparent and some of the newer drugs for the treatment of osteoporosis are yet to be investigated in this subgroup of patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18085426     DOI: 10.1007/s11255-007-9310-y

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  69 in total

1.  MEDICAL AND SURGICAL TREATMENT OF AZOTEMIC OSTEODYSTROPHY.

Authors:  J H FELTS; J E WHITLEY; D D ANDERSON; H M CARPENTER; H H BRADSHAW
Journal:  Ann Intern Med       Date:  1965-06       Impact factor: 25.391

Review 2.  Chronic kidney disease-mineral-bone disorder: a new paradigm.

Authors:  Sharon M Moe; Tilman Drüeke; Norbert Lameire; Garabed Eknoyan
Journal:  Adv Chronic Kidney Dis       Date:  2007-01       Impact factor: 3.620

3.  Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism.

Authors:  Ilan Szwarc; Angel Argilés; Valérie Garrigue; Sylvie Delmas; Guillaume Chong; Sébastien Deleuze; Georges Mourad
Journal:  Transplantation       Date:  2006-09-15       Impact factor: 4.939

Review 4.  RANK ligand inhibition with denosumab for the management of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Expert Opin Biol Ther       Date:  2006-10       Impact factor: 4.388

5.  Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.

Authors:  S M Ali; F J Esteva; G Hortobagyi; H Harvey; J Seaman; R Knight; L Costa; A Lipton
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

6.  Tertiary hyperparathyroidism after renal transplantation: operative indications.

Authors:  A M D'Alessandro; J S Melzer; J D Pirsch; H W Sollinger; M Kalayoglu; W B Vernon; F O Belzer; J R Starling
Journal:  Surgery       Date:  1989-12       Impact factor: 3.982

7.  Effect of ibandronate on bone loss and renal function after kidney transplantation.

Authors:  Wolfgang Grotz; Christian Nagel; Daria Poeschel; Markus Cybulla; Karl-Georg Petersen; Markus Uhl; Christoph Strey; Günter Kirste; Manfred Olschewski; Achim Reichelt; Lars Christian Rump
Journal:  J Am Soc Nephrol       Date:  2001-07       Impact factor: 10.121

8.  The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.

Authors:  Anja E Kruse; Ute Eisenberger; Felix J Frey; Markus G Mohaupt
Journal:  Nephrol Dial Transplant       Date:  2005-06-07       Impact factor: 5.992

9.  The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients.

Authors:  Eugénie C H van den Ham; Jeroen P Kooman; Maarten L Christiaans; Johannes P van Hooff
Journal:  Transpl Int       Date:  2003-01-18       Impact factor: 3.782

10.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

View more
  6 in total

1.  Associations between serum leptin level and bone turnover in kidney transplant recipients.

Authors:  Csaba P Kovesdy; Miklos Z Molnar; Maria E Czira; Anna Rudas; Akos Ujszaszi; Laszlo Rosivall; Miklos Szathmari; Adrian Covic; Andras Keszei; Gabriella Beko; Peter Lakatos; Janos Kosa; Istvan Mucsi
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 8.237

2.  Total parathyroidectomy without autotransplantation after renal transplantation for tertiary hyperparathyroidism: long-term follow-up.

Authors:  Hazim M Sadideen; John D Taylor; David J Goldsmith
Journal:  Int Urol Nephrol       Date:  2011-10-14       Impact factor: 2.370

Review 3.  What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy?

Authors:  Kristina Blaslov; Lea Katalinic; Petar Kes; Goce Spasovski; Ruzica Smalcelj; Nikolina Basic-Jukic
Journal:  Int Urol Nephrol       Date:  2013-11-12       Impact factor: 2.370

4.  Calcium, phosphate and parathyroid metabolism in kidney transplanted patients.

Authors:  Csaba Ambrus; Miklos Zsolt Molnar; Maria Eszter Czira; Laszlo Rosivall; Istvan Kiss; Adam Remport; Miklos Szathmari; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-08-22       Impact factor: 2.370

5.  Spontaneous and simultaneous rupture of both Achilles tendons and pathological fracture of the femur neck in a patient receiving long-term hemodialysis.

Authors:  Kemal Ureten; Mehmet Akif Oztürk; Mustafa Ozbek; Selman Unverdi
Journal:  Int Urol Nephrol       Date:  2008-08-08       Impact factor: 2.370

6.  Ayurvedic Medications as Accelerating Cause of Atraumatic Bilateral Femur Neck Fracture in a Young Indian Male with Kidney Disease: A Unique Case Report.

Authors:  Sharath Kittanakere Ramanath; Rahul Hemant Shah; Y Karthik Pradyumna
Journal:  J Orthop Case Rep       Date:  2019 Jan-Feb
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.